Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.60 |
| ▸ | MMP8 | P22894 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | CPA1 | P15085 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1071045 | 0.93 | MMP9 (0.60) | MMP9MMP8BCHELTA4HNPC1 | |
| SCHEMBL8935277 | 0.93 | MMP9 (0.60) | MMP9MMP8BCHELTA4HNPC1 | |
| SCHEMBL8935472 | 0.93 | MMP9 (0.60) | MMP9MMP8BCHELTA4HNPC1 | |
| SCHEMBL1069240 | 0.90 | MMP9 (0.69) | MMP9MMP8BCHELTA4HMME | |
| SCHEMBL3288556 | 0.90 | MMP9 (0.69) | MMP9MMP8BCHELTA4HMME | |
| SCHEMBL7398737 | 0.89 | MMP9 (0.55) | MMP9MMP8BCHELTA4HNPC1 | |
| SCHEMBL7398741 | 0.89 | MMP9 (0.55) | MMP9MMP8BCHELTA4HNPC1 | |
| SCHEMBL7403575 | 0.88 | MMP9 (0.57) | MMP9MMP8BCHELTA4HNPC1 | |
| SCHEMBL8935375 | 0.88 | MMP9 (0.57) | MMP9MMP8BCHELTA4HNPC1 | |
| SCHEMBL7439130 | 0.86 | MAOB (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267835-A1 | Methods of treating disorders of trigeminalvascular activation | NEWRON PHARMACEUTICALS SPA (IT) | 2010-10-21 | — | — | US | claimed |
| US-7709523-B2 | Alpha-aminoamide derivatives useful as antimigraine agents | NEWRON PHARMACEUTICALS SPA (IT) | 2010-05-04 | — | — | US | claimed |
| EP-1585510-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | NEWRON PHARM SPA (IT) | 2007-12-05 | — | — | EP | claimed |
| US-20060079570-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-04-13 | — | — | US | claimed |
| EP-1585510-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2005-10-19 | — | — | EP | claimed |
| WO-2004062655-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | NEWRON PHARMACEUTICALS SPA (IT) | 2004-07-29 | — | — | WO | claimed |
| EP-1438956-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | Newron Pharmaceuticals S.p.A. (IT) | 2004-07-21 | — | — | EP | claimed |
| US-20100267835-A1 | Methods of treating disorders of trigeminalvascular activation | NEWRON PHARMACEUTICALS SPA (IT) | 2010-10-21 | — | — | US | disclosed |
| US-7709523-B2 | Alpha-aminoamide derivatives useful as antimigraine agents | NEWRON PHARMACEUTICALS SPA (IT) | 2010-05-04 | — | — | US | disclosed |
| EP-1585510-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | NEWRON PHARM SPA (IT) | 2007-12-05 | — | — | EP | disclosed |
| US-20060079570-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-04-13 | — | — | US | disclosed |
| EP-1585510-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004062655-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | NEWRON PHARMACEUTICALS SPA (IT) | 2004-07-29 | — | — | WO | disclosed |
| EP-1438956-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | Newron Pharmaceuticals S.p.A. (IT) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079570-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | AANAT, FAAH, ACHE | MMP9 1109/4885MMP8 1717/4885BCHE 506/4885 |
| US-20100267835-A1 | Methods of treating disorders of trigeminalvascular activation | MVD, TBXA2R, BDKRB2 | MMP9 1865/4885MMP8 534/4885BCHE 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.